Who
Mayur Ian Somaiya
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, NewAmsterdam Pharma Company; Chief Financial Officer, Tcr2 Therapeutics.
In numbers
- Trades disclosed
- 47
- Buys
- 0
- Sells
- 7
- Bought
- $0
- Sold
- $7.0M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 11 Apr 2019
- Last trade
- 21 Jan 2026
- Last filed
- 22 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 Jan 2026filed 22 Jan 2026 | NAMS NewAmsterdam Pharma Companyoption or derivative · Biotechnology | SEC FORM 4 Code M | —39,784 at $0.00 | filing |
| 21 Jan 2026filed 22 Jan 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Code M | $368K39,784 at $9.26 | filing |
| 21 Jan 2026filed 22 Jan 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Sold | $513K15,422 at $33.25 | filing |
| 21 Jan 2026filed 22 Jan 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Sold | $823K24,362 at $33.80 | filing |
| 21 Jan 2026filed 22 Jan 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Code M | $368K39,784 at $9.26 | filing |
| 21 Jan 2026filed 22 Jan 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Sold | $513K15,422 at $33.25 | filing |
| 21 Jan 2026filed 22 Jan 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Sold | $823K24,362 at $33.80 | filing |
| 21 Jan 2026filed 22 Jan 2026 | NAMS NewAmsterdam Pharma Companyoption or derivative · Biotechnology | SEC FORM 4 Code M | —39,784 at $0.00 | filing |
| 20 Jan 2026filed 22 Jan 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Code M | $558K60,216 at $9.26 | filing |
| 20 Jan 2026filed 22 Jan 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Sold | $28K900 at $30.64 | filing |
| 20 Jan 2026filed 22 Jan 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Sold | $1.3M39,712 at $31.78 | filing |
| 20 Jan 2026filed 22 Jan 2026 | NAMS NewAmsterdam Pharma Companyoption or derivative · Biotechnology | SEC FORM 4 Code M | —60,216 at $0.00 | filing |
| 20 Jan 2026filed 22 Jan 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Sold | $635K19,604 at $32.38 | filing |
| 20 Jan 2026filed 22 Jan 2026 | NAMS NewAmsterdam Pharma Companyoption or derivative · Biotechnology | SEC FORM 4 Code M | —60,216 at $0.00 | filing |
| 20 Jan 2026filed 22 Jan 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Code M | $558K60,216 at $9.26 | filing |
| 20 Jan 2026filed 22 Jan 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Sold | $28K900 at $30.64 | filing |
| 20 Jan 2026filed 22 Jan 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Sold | $1.3M39,712 at $31.78 | filing |
| 20 Jan 2026filed 22 Jan 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Sold | $635K19,604 at $32.38 | filing |
| 7 Jan 2026filed 7 Jan 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Code A | —25,500 | filing |
| 7 Jan 2026filed 7 Jan 2026 | NAMS NewAmsterdam Pharma Companyoption or derivative · Biotechnology | SEC FORM 4 Code A | —115,000 at $0.00 | filing |
News
Head-To-Head Analysis: Rallybio (NASDAQ:RLYB) versus NewAmsterdam Pharma (NASDAQ:NAMS)NAMS · dailypolitical.com · 14 Oct 2026Analyzing NewAmsterdam Pharma (NASDAQ:NAMS) & Grifols (NASDAQ:GRFS)NAMS · tickerreport.com · 14 Oct 2026Financial Analysis: NewAmsterdam Pharma (NASDAQ:NAMS) versus Rallybio (NASDAQ:RLYB)NAMS · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name Mayur Ian Somaiya; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.